Please sign in to follow a disease.
5,000 patients worldwide to help perfect cancer staging system
NCT ID NCT07013461
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This international study aims to improve how doctors stage nasopharyngeal cancer by collecting data from 5,000 patients across multiple countries. Researchers will use this information to refine the TNM staging system and combine it with other factors like biomarkers. The goal is to help doctors personalize treatment more accurately. Participants will be followed for five years to track outcomes.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could lead to a more accurate staging system for nasopharyngeal cancer, helping doctors choose the best treatment for each patient and improving outcomes worldwide.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly benefit participants. The results depend on data quality and may take years to influence clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 5,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Dec 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients enrolled in participating centers
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All histologically confirmed nasopharyngeal carcinoma treated between 1 Oct 2025 and 30 Sep 2026 Exclusion Criteria: * Non-epithelial tumors of nasopharynx (including lymphoma, sarcoma of soft tissue, bone/cartilagetumors. mucosal melanoma, salivary type tumors)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nasopharyngeal cancinoma (NPC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The University of Hong Kong-Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can zapping liver and lung tumors boost treatment for nasopharyngeal cancer?
- Can a targeted drug outperform chemotherapy in Tough-to-Treat nasopharyngeal cancer?
- A pill to stop cancer treatment from stealing appetite?
- Can an experimental drug shrink advanced solid tumors?
- Can a Platinum-Free regimen beat nasopharyngeal carcinoma?
- Can a targeted therapy replace harsh chemo in nasopharyngeal cancer?